RAY121
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Antiphospholipid Syndrome (APS)
Conditions
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM), Immune-mediated Necrotizing Myopathy (IMNM), Immune Thrombocytopenia (ITP)
Trial Timeline
Dec 9, 2024 → Apr 30, 2027
NCT ID
NCT06723106About RAY121
RAY121 is a phase 1 stage product being developed by Chugai Pharmaceutical for Antiphospholipid Syndrome (APS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06723106. Target conditions include Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06723106 | Phase 1 | Recruiting |
| NCT06371417 | Phase 1 | Recruiting |
Competing Products
4 competing products in Antiphospholipid Syndrome (APS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| RAY121 | Chugai Pharmaceutical | Phase 1 | 33 |
| Crovalimab + Placebo + VKA | Roche | Phase 2 | 52 |
| Apixaban + Warfarin | Bristol Myers Squibb | Approved | 84 |
| Rivaroxaban | Bayer | Approved | 82 |